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Abstract 
Background 
Underactive bladder (UAB) is considered the symptom complex associated with the urodynamic 
diagnosis of detrusor underactivity (DU). 
Objective 
The aim of this research was to investigate the patient reported experience of the symptoms, signs 
and impact of underactive bladder (UAB). This research is also part of the initial qualitative phase for 
the development of a new patient reported outcome (PRO) measure for the assessment of UAB.  
Design, Setting and Participants 
Qualitative methods were used to understand the experience of UAB from a patient perspective, in a 
purposive sample of male (n=29) and female (n=15) patients aged 27-88 years (mean: 64 years), 
diagnosed with a primary diagnosis of DU, with or without co-existing urological conditions. Semi-
structured interviews were conducted in Bristol, UK.  
Results  
Male and female patients reported a variety of lower urinary tract symptoms and associated impact 
on quality of life. Storage symptoms of nocturia, increased daytime frequency and urgency, and the 
voiding symptoms of slow stream, hesitancy and straining were reported by over half of the 
patients. A sensation of incomplete emptying and post-micturition dribble were also frequently 
described. Most had a post void residual >30ml (n=34, 77%, median: 199ml) with many reporting 
urinary tract infections, a history of self-catheterisation and some experiencing occasional acute 
retention episodes. These symptoms and signs can have a broad impact on quality of life including 
having to plan their daily activities around the location of toilets, disruption to sleep, social life and 
associated effect on family and friends.  
Conclusions 
Knowledge of the lived experience of UAB obtained in the current study will be used for the 
development of a new PRO measure and help inform the current working definition of UAB. 
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Patient summary 
The symptoms, signs and impact on quality of life of underactive bladder are described by patients 
with the condition.  
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1. Introduction 
Underactive bladder (UAB), which is considered to be the symptom complex of urodynamically 
diagnosed detrusor underactivity (DU), is a condition that is relatively under-researched. The current 
working definition describes UAB as “characterised by prolonged urination time with or without 
sensation of incomplete bladder emptying, usually with hesitancy, reduced sensation on filling, and a 
slow stream” [1].  
In men and women presenting with lower urinary tract symptoms (LUTS) and referred to 
urodynamic studies, the prevalence of DU has been shown to be up to 40% in men and 13% in 
women [2] and as much as 48% in particular groups such as male patients over 70 years of age [3]. In 
men, DU has been reported alongside co-existing bladder outlet obstruction (BOO) or detrusor 
overactivity (DO) in 47% of subjects, and with co-existing DO or urodynamic stress urinary 
incontinence (SUI) in 73% of female subjects [2]. It is recognised that there is an overlap of LUTS 
associated with these conditions and UAB, such as slow flow, nocturia, increased urinary frequency 
and incontinence [1,4,5]. The symptomatic burden of LUTS associated with DU [5-7] and known 
impact of LUTS on quality of life [8,9] highlight the requirement to understand how the patient with 
UAB feels and functions for clinical outcome assessment purposes.  
Currently, no fully validated patient reported outcome (PRO) measures exist for the assessment of 
UAB. In order for a PRO instrument to be used in patient management, exploration of the reported 
symptoms, signs or other functional aspects should be carried out in a sample of patients known to 
have the condition, using accepted qualitative methodology. In this type of study an exact 
representative sample is not required, but a good spread of participant characteristics is 
advantageous in order to capture all relevant backgrounds and experiences of the condition [10]. 
There is no definitive sample size for a study such as this but thirty or forty interviews are typical 
[9,11,12]. To our knowledge, this is the first qualitative research study which focuses on elucidating 
the patient reported experience of UAB. This study also aims to contribute essential evidence of 
content validity for a new PRO measure [13,14], for the assessment of the symptoms, signs and 
impact of UAB in research and clinical practice. 
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2. Material and Methods 
Qualitative methods were employed in order to understand the experience of UAB from a patient 
perspective. Semi-structured interviews were conducted with a purposive sample of male and 
female patients with a primary diagnosis of DU. Patients with DU alone and in combination with 
other common co-existing urological conditions, were interviewed to ensure the relevance of the 
PRO instrument to all patients with the condition. The primary objective to the interviews was to 
elicit the symptoms, signs and impact of UAB, with an emphasis on capturing key idiomatic 
expressions and language used to describe their symptoms. 
Interviews were conducted by trained qualitative researchers either in-person at the patient’s home, 
in situ at the hospital, or over the phone. Informed written consent was obtained to participate and 
audio record the interviews, which were then transcribed verbatim and organised using qualitative 
research software package NVivo v10. Following the first exploratory interviews, an inductive 
approach [15] to analysis of the transcripts revealed concepts that contributed to the ongoing 
development of a coding framework. Concepts identified early on in the coding process were 
followed-up in subsequent interviews through iterative revisions of an interview schedule. Data 
collection and analysis continued concurrently, using a reflexive and constant comparison approach 
[16]. Concepts relating to symptom or impacts which were spontaneously reported in the interview 
(without prompting by the interviewer) were given particular attention. Towards the end of data 
collection, concepts were coded by urologic defined symptoms (e.g. ‘hesitancy’, ‘increased urinary 
frequency’, ‘urgency’) which categorized the data within the current urological and theoretical 
context [17,18]. Discussion meetings between researchers evaluated discrepant codes to achieve 
consensus and consistent coding across transcripts. Interviews continued until the dataset was 
considered saturated, that is, when it was considered that no further concepts relevant to DU were 
likely to be found by conducting further interviews. Ethics approval was granted as a substantial 
amendment of an existing project: Reference 087/99. 
Sample inclusion criteria 
Male and female subjects of 18 years of age or over with a slow stream associated with a weak 
bladder contraction, were selected by retrospective review of the urodynamic reports of patients 
referred for pressure flow studies (PFS). Table 1 shows the urodynamic criteria used to select 
subjects with a primary diagnosis of DU. The patients were grouped by the presence or absence of 
co-existing urological conditions.  
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3. Results 
A total of 44 semi-structured interviews were conducted in Bristol, UK, from Jan - Dec 2014. Table 2 
summarises the demographic and clinical characteristics of the sample. All patients were Caucasian, 
and came from a variety of educational backgrounds (ranging from school leaver at 16 or younger, to 
college or university educated) and occupations (manual, service and professional). 
It was confirmed that saturation had been achieved by the first 12 (out of 19) interviews in patients 
with DU (without co-existing urological conditions). Further exploration was required in the 
diagnostic groups that included co-existing urological conditions as isolated minor concepts were still 
being elicited. Ultimately, these were all considered to be sub-concepts of already elicited symptoms 
or unlikely to be related to DU. 
The content analysis revealed that patients reported a range of LUTS that could have an associated 
impact on quality of life. More than 20 storage, voiding and other urological signs and symptoms 
were described by the patients, as illustrated in figure 1, along with the indication of relative 
prevalence. The following summarises the main findings and the supplementary material online 
provides further detail including additional representative quotes from the patient’s accounts. 
Storage symptoms 
The storage symptoms reported by over half of the patients included nocturia, increased daytime 
frequency and urgency. These were reported by both sexes, often spontaneously (without 
prompting) and frequently associated with a high degree of bother. Nocturia and/or nocturnal voids 
was the most commonly reported overall symptom (n=34, 77%), as most patients described having 
to get out of bed at least once in the night to urinate. Patients reported a frequency of micturition 
from once or twice to over 12 urinations per day. This was often associated with urgency, the need 
to immediately re-void or ‘clustering’ of voids at certain times of day. Urinary incontinence occurred 
in all diagnostic groups and was very bothersome, but was mainly associated with patients who 
demonstrated DU and co-existing conditions (DO and SUI) during PFS. The reduced sensation of the 
ability to detect the fullness of the bladder was described by a minority of patients (n=5, 11%). 
P36: “I’m getting up every night two or three times, average twice a night and not getting very good 
sleep”  
P34: “Just constantly going back and to and from the toilet” 
P22: “I can feel it coming on and then all of a sudden I think gosh I’ve got to go” 
 Voiding symptoms 
The voiding symptoms described by the majority of patients (>50%) included a slow stream, 
hesitancy and straining. These were often spontaneously reported by either gender with high degree 
of associated bother. The combination of these symptoms in individual patients could result in 
extended voiding time and lengthy stays in the bathroom. The strength of the urinary stream was 
described as ‘slow’ or ‘weak’, and could be unpredictable or variable. Patients described ‘having to 
wait’ or ‘concentrate’ before the urine flow would begin, usually for a few seconds but was up to 20 
minutes in one male patient. Straining could be described as ‘pushing’ or ‘squeezing’ and was used 
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to initiate or maintain the flow, or to try and make sure the bladder was empty at the end of 
micturition. An intermittent stream, spraying of the flow (in men) and urinations of small volume per 
void were also reported.  
P21: “Stopping and starting with a very weak flow, then I could stand in front of the loo for at least 
three or four minutes and nothing happens”  
P39 “It's a combination of sort of mental and physical cajoling to make it start.” 
P12: “There would be very little natural flow and the majority of the flow would be as a result of 
having to strain” 
Post-micturition symptoms 
A sensation of incomplete emptying of the bladder (n=19, 43%), often resulting in the need to re-
void within a short period of time was frequently described by patients in all diagnostic groups. A 
post-micturition dribble was reported almost exclusively by men in this sample (n=17, 39%). Lower 
urinary tract pain was reported by 25% of patients (n=11) but the accounts were variable with 
regard to the type, source and severity of pain experienced. 
P12: “I know I need to do more and I can’t. That seems to be the biggest annoyance because I’ll have 
to go again in a short period of time rather than a proper emptying of the bladder” 
P6: “Usually when I have put myself together again after I’ve urinated I do a little bit again” 
Other signs or symptoms 
Many of the patients were either currently or had historically been performing self-catheterisation 
(n=23, 52%), and had experienced recurrent urinary tract infections for which they had sought 
treatment in the past (n=17, 39%). Four patients from the DU diagnostic group described occasional 
episodes where they were unable to perform a volitional void, and they would return to pass urine 
successfully a short time after. In isolated incidents, six patients had acute retention episodes that 
required hospital admission for catheterisation. A minority of patients (n=8, 18%) had bowel issues 
(e.g. constipation) and two female patients noticed an association of these with the reported 
severity of their lower urinary tract symptoms. 
P14: “My biggest concern quite honestly is the catheter one way and another, what with infections 
and so on” 
P21: “Now and again which is very rare I just cannot go. I can actually go to the loo about four or five 
times and I just cannot perform at all” 
Impact 
The impact of their symptoms on quality of life was highly variable among different individuals. 
Some described the negative consequences on their lives, whilst others reported relatively little 
inconvenience saying they had become ‘used to it’ due to the chronic nature of their condition 
(n=12, 27%). In particular, the symptoms of high urinary frequency, nocturnal voids and urgency 
caused a reliance on planning their daily activities around the location of toilets (n=27, 61%) and 
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daytime somnolence as a result of interrupted sleep (n=14, 32%). The ensuing disruption to social, 
work-life or physical activities could be very bothersome. The consequence was an impact on self-
image or confidence, feelings of embarrassment in certain situations, and impact on relationships 
with family and friends, including sex-life for a minority of patients. The control of fluid intake was 
one way patients often sought to manage their symptoms (n=15, 34%).   
P1: “It makes life uncomfortable, I’m always looking to be somewhere near the loo so I can go if I 
need to” 
P12: I couldn’t start the urine flow very easily and I became a bit embarrassed by that situation 
because I was just stood there doing nothing” 
P22: “It does interfere with my social life, and sleep as well” 
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4. Discussion 
To our knowledge, this is the first study to explore and document the patient reported experience of 
UAB, elicited from a purposive sample of male and female patients with a primary diagnosis of DU. 
The result is a comprehensive patient-centered description of the symptoms, signs and impact of 
UAB, revealing the condition to be a myriad of storage and voiding LUTS. 
The storage symptoms of nocturia, high urinary frequency, urgency and incontinence and voiding 
symptoms of slow stream, hesitancy and straining were most commonly reported by both male and 
female patients. Straining (to initiate, maintain or finish urination) is of particular note as it was well 
represented in the DU diagnostic group and is not currently included in the 2015 UAB symptomatic 
definition [1]. These classic LUTS are consistent with a weak bladder contraction and are in 
accordance with symptoms associated with DU in the literature [5-7]. The current study also 
corroborated recent findings by Gammie et al [19] which associated a feeling of incomplete 
emptying, absent or reduced sensation and a variety of bowel issues to DU patients. A PVR of >30mls 
(median: 199ml) was present in the majority of participants, and a large proportion of patients were 
currently or had historically self-catheterised and/or had urinary tract infections, as well as some 
who had experienced acute retention episodes.  
Previous research supports the findings that there can be a broad impact on patient’s lives 
associated with LUTS [20,21]. The requirement to plan ahead around the location of toilets, 
disruption to sleep, embarrassment in certain situations, and consequent effect on social life, self-
esteem and confidence are supported by other qualitative studies in male and female patients with 
LUTS [9,22,23]. Many of the patients with UAB experienced similar levels of impact but others felt 
they were able to manage their symptoms to minimise the impact on their lives.  
The current study provides a robust evidence base on which to base the development of a PRO 
instrument to evaluate interventions for UAB. A number of symptoms, signs and areas of impact 
were identified that may provide sensitive indicators of improvement or deterioration in UAB 
following treatment. However, there are several challenges to the development of a specific UAB 
PRO measure. Some of the commonly reported symptoms may have multiple aetiologies, such as 
pain or nocturia, which may be a consequence of other health or behavioural factors unrelated to 
lower urinary tract dysfunction [24-26]. The overlap of the reported symptoms in patients with co-
existing OAB or BOO is already recognised [5,7] and will be investigated further in later quantitative 
PRO measure validation studies. 
A strength of this study is that all patients were clinically verified to have a primary diagnosis of DU 
by PFS. In addition, those with co-existing urological conditions were included to ensure the 
relevance of the PRO measure to the whole spectrum of DU patients. The study is not intended to 
produce representative epidemiological data but to elicit the overall patient experience of UAB. The 
further elucidation of symptom prevalence and bother will be possible later in the PRO measure 
development process. This study also cannot be used to link UAB to urodynamic DU. Further 
interviews with patients from the United States and Japan are scheduled in order to explore 
potential differences in how patients from other cultures and ethnicities describe UAB symptoms.  
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5. Conclusions 
The current study describes the progress in our understanding of how the clinical diagnosis of DU 
manifests as symptoms, by a thorough exploration of the lived experience of patients. This 
knowledge supports the development of a PRO measure for the outcome assessment of UAB for use 
in trials, research and clinical practice and is valuable to the further development of the definition of 
UAB. 
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Figure 1. Prevalence of symptoms and signs reported in the total sample. The proportion reported 
by patients with DU, and by those with DU and co-existing urological conditions are shown. 
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Table 1. Diagnosis group inclusion criteria and number of patients per diagnosis group. 
All DU patients included in the study (n=44) 
Males:      BCI <100 
                    BOOI <20 
Females:   pdetQmax <20 cmH20 
                   Qmax <15ml/s 
DU without co-existing urological conditions (n=19) 
DU + co-existing urological conditions (n=25) 
Mild SUI/USI (n=7) Mild DO (n=8) BOO-E (n=5) 
BOOI ≥20 - <40 
BOO (n=5) 
BOOI≥40 
Abbreviations: Detrusor pressure at maximum flow (pdetQmax), maximum flow rate (Qmax), bladder 
contractility index (BCI) calculated by BCI=pdetQmax+5Qmax, Bladder Outlet Obstruction Index (BOOI) 
calculated by BOOI=pdetQmax-2Qmax. 
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Table 2. Sample demographic and clinical characteristics. 
Clinical or demographic 
characteristic 
Total sample DU  DU + co-existing 
urological 
conditions 
n 44 19 25 
Mean age and range 
(years) 
64 (27-88) 59 (27-88) 68 (38-87) 
Gender, male n (%) 29 (66) 12 (63) 17 (68) 
Intermittent self-
catheterisation n (%) 
(Historical or current) 
23 (52) 10 (53) 13 (52) 
PVR >30ml* n (%) 34 (77) 14 (74) 20 (80) 
PVR >30ml* (ml) (median 
and interquartile range) 
199 (100-492) 335 (119-492) 170 (100-360) 
BCI (median and 
interquartile range) 
62 (49-79) 62 (48-82) 62 (50-77) 
BOOI (median and 
interquartile range)** 
18 (8-28) 15 (6-18) 25 (9-41) 
pdetQmax (cmH20) (median 
and interquartile range) 
25 (12-35) 24 (12-29) 26 (12-36) 
Qmax (ml/sec) (median and 
interquartile range) 
8 (6-10) 8 (6-11) 6 (5-9) 
*In the absence of any evidence base for the lower limit of a ‘significant’ PVR we chose >30mls. 
**Males only 
Abbreviations: Detrusor pressure at maximum flow (pdetQmax), maximum flow rate (Qmax), bladder contractility 
index (BCI) calculated by BCI=pdetQmax+5Qmax, Bladder Outlet Obstruction Index (BOOI) calculated by 
BOOI=pdetQmax-2Qmax, Post Void Residual (PVR).  
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